Abstract
Keywords
Manufacturer-Specific Translation of ICD Programming Recommendations ǂThe manufacturer-specific programming settings/choices set forth below are based on a compilation of clinical expertise and clinical trial data as reported in the 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal Implantable Cardioverter-Defibrillator Programming and Testing, of which this Appendix B is a part. These recommended settings/choices represent a diligent and good faith effort on the part of the writing committee to translate the consensus statement recommendations to device settings/choices for the four specified clinical issues/implantable cardioverter-defibrillator (ICD) therapies where the writing committee considered that there was sufficient consensus and supporting data to make recommendations intended to improve the safety, morbidity, and mortality profile of patients with these clinical issues/ICD therapies. They are the recommendations of the writing committee only. They do not represent the position or recommendations of HRS, EHRA, LAHRS (formerly SOLAECE), or APHRS, nor are they the manufacturer’s nominal settings or the precise programming tested during clinical trials of these devices, nor are they necessarily the settings/choices that would be recommended by the manufacturer. These recommended settings/choices are not applicable in all circumstances. As stated in the Introduction to the consensus statement, “The care of individual patients must be provided in context of their specific clinical condition and the data available on that patient.” Each treating physician must carefully consider the circumstances of their individual patient and determine whether these recommended settings/choices are appropriate to their patient’s circumstances.ǂThe manufacturer-specific programming settings/choices set forth below are based on a compilation of clinical expertise and clinical trial data as reported in the 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal Implantable Cardioverter-Defibrillator Programming and Testing, of which this Appendix B is a part. These recommended settings/choices represent a diligent and good faith effort on the part of the writing committee to translate the consensus statement recommendations to device settings/choices for the four specified clinical issues/implantable cardioverter-defibrillator (ICD) therapies where the writing committee considered that there was sufficient consensus and supporting data to make recommendations intended to improve the safety, morbidity, and mortality profile of patients with these clinical issues/ICD therapies. They are the recommendations of the writing committee only. They do not represent the position or recommendations of HRS, EHRA, LAHRS (formerly SOLAECE), or APHRS, nor are they the manufacturer’s nominal settings or the precise programming tested during clinical trials of these devices, nor are they necessarily the settings/choices that would be recommended by the manufacturer. These recommended settings/choices are not applicable in all circumstances. As stated in the Introduction to the consensus statement, “The care of individual patients must be provided in context of their specific clinical condition and the data available on that patient.” Each treating physician must carefully consider the circumstances of their individual patient and determine whether these recommended settings/choices are appropriate to their patient’s circumstances.
Abbott (Formerly St. Jude Medical)
Brady |
Single Chamber
Dual Chamber
CRT |
Detection |
In patients with no VT history
In patients where VT CL is known |
1 Fewer intervals to detect may be reasonable due to the possibility of VT straddling 2 zones that may result in “binning” to both zones, effectively doubling time to detect. Beats that fall out of zone sometimes reset counters so patients with poor sensing should also have fewer detection intervals considered. | |
Therapy |
|
2 Rarely, hemodynamically stable slow VT can be treated without programming a back-up shock. | |
SVT Discriminators3 |
Single Chamber
Dual Chamber/CRT-D |
3 SVT Discriminators are not required in Complete Heart Block. | |
Oversensing Rejection |
|
Manufacturer-Specific Translation of ICD Programming Recommendations ǂThe manufacturer-specific programming settings/choices set forth below are based on a compilation of clinical expertise and clinical trial data as reported in the 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal Implantable Cardioverter-Defibrillator Programming and Testing, of which this Appendix B is a part. These recommended settings/choices represent a diligent and good faith effort on the part of the writing committee to translate the consensus statement recommendations to device settings/choices for the four specified clinical issues/implantable cardioverter-defibrillator (ICD) therapies where the writing committee considered that there was sufficient consensus and supporting data to make recommendations intended to improve the safety, morbidity, and mortality profile of patients with these clinical issues/ICD therapies. They are the recommendations of the writing committee only. They do not represent the position or recommendations of HRS, EHRA, LAHRS (formerly SOLAECE), or APHRS, nor are they the manufacturer’s nominal settings or the precise programming tested during clinical trials of these devices, nor are they necessarily the settings/choices that would be recommended by the manufacturer. These recommended settings/choices are not applicable in all circumstances. As stated in the Introduction to the consensus statement, “The care of individual patients must be provided in context of their specific clinical condition and the data available on that patient.” Each treating physician must carefully consider the circumstances of their individual patient and determine whether these recommended settings/choices are appropriate to their patient’s circumstances.ǂThe manufacturer-specific programming settings/choices set forth below are based on a compilation of clinical expertise and clinical trial data as reported in the 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal Implantable Cardioverter-Defibrillator Programming and Testing, of which this Appendix B is a part. These recommended settings/choices represent a diligent and good faith effort on the part of the writing committee to translate the consensus statement recommendations to device settings/choices for the four specified clinical issues/implantable cardioverter-defibrillator (ICD) therapies where the writing committee considered that there was sufficient consensus and supporting data to make recommendations intended to improve the safety, morbidity, and mortality profile of patients with these clinical issues/ICD therapies. They are the recommendations of the writing committee only. They do not represent the position or recommendations of HRS, EHRA, LAHRS (formerly SOLAECE), or APHRS, nor are they the manufacturer’s nominal settings or the precise programming tested during clinical trials of these devices, nor are they necessarily the settings/choices that would be recommended by the manufacturer. These recommended settings/choices are not applicable in all circumstances. As stated in the Introduction to the consensus statement, “The care of individual patients must be provided in context of their specific clinical condition and the data available on that patient.” Each treating physician must carefully consider the circumstances of their individual patient and determine whether these recommended settings/choices are appropriate to their patient’s circumstances.
BIOTRONIK
Brady |
Single Chamber
Dual Chamber
CRT |
Detection |
In patients with no VT history1
In patients where VT CL is known |
1 SVT discriminators are linked to Detection Zones. An alternative configuration would be VF 250bpm, VT2 231bpm and VT1 188bpm with therapy (i.e., no Monitor zone) if >1 ATP attempt desired up to 250bpm. | |
Therapy |
|
2 If programmable, otherwise 85%. 3 Rarely, hemodynamically stable slow VT can be treated without programming a back-up shock. | |
SVT Discriminators4 |
Single Chamber
Dual Chamber/CRT-D |
4 SVT Discriminators are not required in Complete Heart Block. 5 MorphMatch is recommended for patients with narrow QRS complexes and sufficient far-field amplitude. Otherwise, Onset 20% and Stability 48ms is a recommended alternative. 6 If Onset is programmed ON, the performance of this discriminator is enhanced with a Monitoring Zone enabled. | |
Others |
|
Manufacturer-Specific Translation of ICD Programming Recommendations ǂThe manufacturer-specific programming settings/choices set forth below are based on a compilation of clinical expertise and clinical trial data as reported in the 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal Implantable Cardioverter-Defibrillator Programming and Testing, of which this Appendix B is a part. These recommended settings/choices represent a diligent and good faith effort on the part of the writing committee to translate the consensus statement recommendations to device settings/choices for the four specified clinical issues/implantable cardioverter-defibrillator (ICD) therapies where the writing committee considered that there was sufficient consensus and supporting data to make recommendations intended to improve the safety, morbidity, and mortality profile of patients with these clinical issues/ICD therapies. They are the recommendations of the writing committee only. They do not represent the position or recommendations of HRS, EHRA, LAHRS (formerly SOLAECE), or APHRS, nor are they the manufacturer’s nominal settings or the precise programming tested during clinical trials of these devices, nor are they necessarily the settings/choices that would be recommended by the manufacturer. These recommended settings/choices are not applicable in all circumstances. As stated in the Introduction to the consensus statement, “The care of individual patients must be provided in context of their specific clinical condition and the data available on that patient.” Each treating physician must carefully consider the circumstances of their individual patient and determine whether these recommended settings/choices are appropriate to their patient’s circumstances.ǂThe manufacturer-specific programming settings/choices set forth below are based on a compilation of clinical expertise and clinical trial data as reported in the 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal Implantable Cardioverter-Defibrillator Programming and Testing, of which this Appendix B is a part. These recommended settings/choices represent a diligent and good faith effort on the part of the writing committee to translate the consensus statement recommendations to device settings/choices for the four specified clinical issues/implantable cardioverter-defibrillator (ICD) therapies where the writing committee considered that there was sufficient consensus and supporting data to make recommendations intended to improve the safety, morbidity, and mortality profile of patients with these clinical issues/ICD therapies. They are the recommendations of the writing committee only. They do not represent the position or recommendations of HRS, EHRA, LAHRS (formerly SOLAECE), or APHRS, nor are they the manufacturer’s nominal settings or the precise programming tested during clinical trials of these devices, nor are they necessarily the settings/choices that would be recommended by the manufacturer. These recommended settings/choices are not applicable in all circumstances. As stated in the Introduction to the consensus statement, “The care of individual patients must be provided in context of their specific clinical condition and the data available on that patient.” Each treating physician must carefully consider the circumstances of their individual patient and determine whether these recommended settings/choices are appropriate to their patient’s circumstances.
Boston Scientific
Brady |
Single Chamber
Dual Chamber
CRT |
Detection |
In patients with no VT history
In patients where VT cycle length is known |
Therapy |
|
1 Rarely, hemodynamically stable slow VT can be treated without programming a back-up shock. | |
SVT Discriminators2 |
ICD
CRT-D |
2 SVT Discriminators are not required in Complete Heart Block. | |
Oversensing Rejection |
|
Others |
|
SUBCUTANEOUS ICD Settings: |
|
Manufacturer-Specific Translation of ICD Programming Recommendations ǂThe manufacturer-specific programming settings/choices set forth below are based on a compilation of clinical expertise and clinical trial data as reported in the 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal Implantable Cardioverter-Defibrillator Programming and Testing, of which this Appendix B is a part. These recommended settings/choices represent a diligent and good faith effort on the part of the writing committee to translate the consensus statement recommendations to device settings/choices for the four specified clinical issues/implantable cardioverter-defibrillator (ICD) therapies where the writing committee considered that there was sufficient consensus and supporting data to make recommendations intended to improve the safety, morbidity, and mortality profile of patients with these clinical issues/ICD therapies. They are the recommendations of the writing committee only. They do not represent the position or recommendations of HRS, EHRA, LAHRS (formerly SOLAECE), or APHRS, nor are they the manufacturer’s nominal settings or the precise programming tested during clinical trials of these devices, nor are they necessarily the settings/choices that would be recommended by the manufacturer. These recommended settings/choices are not applicable in all circumstances. As stated in the Introduction to the consensus statement, “The care of individual patients must be provided in context of their specific clinical condition and the data available on that patient.” Each treating physician must carefully consider the circumstances of their individual patient and determine whether these recommended settings/choices are appropriate to their patient’s circumstances.ǂThe manufacturer-specific programming settings/choices set forth below are based on a compilation of clinical expertise and clinical trial data as reported in the 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal Implantable Cardioverter-Defibrillator Programming and Testing, of which this Appendix B is a part. These recommended settings/choices represent a diligent and good faith effort on the part of the writing committee to translate the consensus statement recommendations to device settings/choices for the four specified clinical issues/implantable cardioverter-defibrillator (ICD) therapies where the writing committee considered that there was sufficient consensus and supporting data to make recommendations intended to improve the safety, morbidity, and mortality profile of patients with these clinical issues/ICD therapies. They are the recommendations of the writing committee only. They do not represent the position or recommendations of HRS, EHRA, LAHRS (formerly SOLAECE), or APHRS, nor are they the manufacturer’s nominal settings or the precise programming tested during clinical trials of these devices, nor are they necessarily the settings/choices that would be recommended by the manufacturer. These recommended settings/choices are not applicable in all circumstances. As stated in the Introduction to the consensus statement, “The care of individual patients must be provided in context of their specific clinical condition and the data available on that patient.” Each treating physician must carefully consider the circumstances of their individual patient and determine whether these recommended settings/choices are appropriate to their patient’s circumstances.
Medtronic
Brady |
Single Chamber
Dual Chamber
CRT |
Detection |
In patients with no VT history
In patients where VT CL is known |
1 Use of ATP Before/During Charging in the VF zone achieves similar functionality as use of the FVT zone. Multi-zone programming using FVT may allow tiered ATP therapy. 2 Consecutive count in VT zone; hence, lower NID as per PainFree SST data. | |
Therapy |
|
3 Rarely, hemodynamically stable slow VT can be treated without programming a back-up shock. | |
SVT Discriminators4 |
Single Chamber
Dual Chamber/CRT-D |
4 SVT Discriminators are not required in Complete Heart Block. | |
Oversensing Rejection |
|
Manufacturer-Specific Translation of ICD Programming Recommendations ǂThe manufacturer-specific programming settings/choices set forth below are based on a compilation of clinical expertise and clinical trial data as reported in the 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal Implantable Cardioverter-Defibrillator Programming and Testing, of which this Appendix B is a part. These recommended settings/choices represent a diligent and good faith effort on the part of the writing committee to translate the consensus statement recommendations to device settings/choices for the four specified clinical issues/implantable cardioverter-defibrillator (ICD) therapies where the writing committee considered that there was sufficient consensus and supporting data to make recommendations intended to improve the safety, morbidity, and mortality profile of patients with these clinical issues/ICD therapies. They are the recommendations of the writing committee only. They do not represent the position or recommendations of HRS, EHRA, LAHRS (formerly SOLAECE), or APHRS, nor are they the manufacturer’s nominal settings or the precise programming tested during clinical trials of these devices, nor are they necessarily the settings/choices that would be recommended by the manufacturer. These recommended settings/choices are not applicable in all circumstances. As stated in the Introduction to the consensus statement, “The care of individual patients must be provided in context of their specific clinical condition and the data available on that patient.” Each treating physician must carefully consider the circumstances of their individual patient and determine whether these recommended settings/choices are appropriate to their patient’s circumstances.ǂThe manufacturer-specific programming settings/choices set forth below are based on a compilation of clinical expertise and clinical trial data as reported in the 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal Implantable Cardioverter-Defibrillator Programming and Testing, of which this Appendix B is a part. These recommended settings/choices represent a diligent and good faith effort on the part of the writing committee to translate the consensus statement recommendations to device settings/choices for the four specified clinical issues/implantable cardioverter-defibrillator (ICD) therapies where the writing committee considered that there was sufficient consensus and supporting data to make recommendations intended to improve the safety, morbidity, and mortality profile of patients with these clinical issues/ICD therapies. They are the recommendations of the writing committee only. They do not represent the position or recommendations of HRS, EHRA, LAHRS (formerly SOLAECE), or APHRS, nor are they the manufacturer’s nominal settings or the precise programming tested during clinical trials of these devices, nor are they necessarily the settings/choices that would be recommended by the manufacturer. These recommended settings/choices are not applicable in all circumstances. As stated in the Introduction to the consensus statement, “The care of individual patients must be provided in context of their specific clinical condition and the data available on that patient.” Each treating physician must carefully consider the circumstances of their individual patient and determine whether these recommended settings/choices are appropriate to their patient’s circumstances.
MicroPort CRM (Formerly LivaNova and Sorin Group)
Brady |
Single Chamber
Dual Chamber
CRT |
1 Requires SonRtip atrial lead with integrated hemodynamic sensor. | |
Detection |
In patients with no VT history
In patients where VT CL is known |
Therapy |
|
2 Satisfaction of stability (nominal value = 30ms) in the Fast VT zone will not prevent therapy but rather activate programmable burst pacing prior to shock therapy. 3 Rarely, hemodynamically stable slow VT can be treated without programming a back-up shock. | |
SVT Discriminators4 |
Single Chamber
Dual Chamber/CRT-D |
4 SVT Discriminators are not required in Complete Heart Block. | |
Oversensing Rejection |
|
Appendix
Writing group member | Employment | Honoraria/Speaking/Consulting | Speakers’ bureau | Research | Fellowship support | Ownership/Partnership/Principal/Majority stockholder | Stock or stock options | Intellectual property/Royalties | Other |
---|---|---|---|---|---|---|---|---|---|
Martin K. Stiles, MBChB, PhD, FHRS (Chair) | Waikato Hospital, Hamilton, New Zealand | None | None | None | None | None | None | None | None |
Laurent Fauchier, MD, PhD | Centre Hospitalier Universitaire Trousseau, Université François Rabelais, Tours, France | 1: BMS/Pfizer; 1: Boehringer Ingelheim; 1: Medtronic; 1: Novartis; 2: Bayer HealthCare | None | None | None | None | None | None | None |
Carlos A. Morillo, MD, FHRS | Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Canada | 1: Abbott; 1: Bayer; 1: BMS/Pfizer; 1: Medtronic; 1: Servier | None | None | None | None | None | None | None |
Bruce L. Wilkoff, MD, FHRS, CCDS | Cleveland Clinic, Cleveland, Ohio | 1: Abbott Vascular; 2: Medtronic; 2: Philips | None | None | None | None | None | None | None |
Peer reviewer | Employment | Honoraria/Speaking/Consulting | Speakers’ bureau | Research | Fellowship support | Ownership/Partnership/Principal/Majority stockholder | Stock or stock options | Intellectual property/Royalties | Other |
---|---|---|---|---|---|---|---|---|---|
Serge Boveda, MD, PhD | Cardiology Department, Clinique Pasteur, Toulouse, France | 1: Boston Scientific; 1: Medtronic; 1: MicroPort | None | None | None | None | None | None | None |
Michael R. Gold, MD, PhD, FHRS | Medical University of South Carolina, Charleston, South Carolina | 1: Abbott Vascular; 1: EBR Systems; 1: Medtronic; 2: Boston Scientific | None | None | None | None | None | None | 1: ABIM |
Roberto Keegan, MD | Hospital Privado del Sur and Hospital Español, Bahia Blanca, Argentina | None | None | None | None | None | None | None | None |
Valentina Kutyifa, MD, PhD, FHRS, FESC, FACC | University of Rochester Medical Center, Rochester, New York; Adjunct Position at Semmelweis University Heart Center, Budapest, Hungary | 1: Biotronik; 1: ZOLL Medical Corporation | None | 5: Biotronik; 5: Boston Scientific; 5: ZOLL Medical Corporation | None | None | None | None | None |
Chu-Pak Lau, MD, FHRS, CCDS | The University of Hong Kong, Hong Kong, Hong Kong | None | None | None | None | None | None | None | None |
Mark A. McGuire, MBBS, PhD | Heart Rhythm Centre, Newtown, Australia | 1: Medtronic | None | None | None | None | None | None | None |
Siva K. Mulpuru, MD, FHRS, CCDS | Mayo Clinic Arizona, Phoenix, Arizona | None | 0: Medtronic | None | None | None | None | None | None |
David J. Slotwiner, MD, FHRS | Weill Cornell Medical College, New York, New York | None | None | None | None | None | None | None | None |
William Uribe, MD, MBA, FHRS | CES Cardiología, Medellin, Colombia | 1: Abbot Laboratories; 1: Pfizer | None | None | None | None | None | None | None |
Article info
Publication history
Footnotes
Document Reviewers: Serge Boveda, MD, PhD; Michael R. Gold, MD, PhD, FHRS; Roberto Keegan, MD; Valentina Kutyifa, MD, PhD, FHRS, FESC, FACC; Chu-Pak Lau, MD, FHRS, CCDS; Mark A. McGuire, MBBS, PhD; Siva K. Mulpuru, MD, FHRS, CCDS; David J. Slotwiner, MD, FHRS; William Uribe, MD, MBA, FHRS
Developed in partnership with and endorsed by the European Heart Rhythm Association (EHRA), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS).
For copies of this document, please contact the Elsevier Inc. Reprint Department ([email protected]). Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the Heart Rhythm Society. Instructions for obtaining permission are located at https://www.elsevier.com/about/our-business/policies/copyright/permissions.
This article has been copublished in Europace and the Journal of Arrhythmia.
Correspondence: Heart Rhythm Society, 1325 G Street NW, Suite 400, Washington, DC 20005. E-mail address: [email protected]
Identification
Copyright
User license
Creative Commons Attribution (CC BY 4.0) |
Permitted
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy